Market revenue in 2023 | USD 33.4 million |
Market revenue in 2030 | USD 52.3 million |
Growth rate | 6.6% (CAGR from 2023 to 2030) |
Largest segment | Biomarker services |
Fastest growing segment | Genetic Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Genetic Services, Biomarker Services, Microbiology Services, Anatomic Pathology/Histology, Specimen Management & Storage, Special Chemistry Services |
Key market players worldwide | LabConnect, Eurofins Scientific SE, A. P. Moller Maersk A/S ADR, ACM Global, Cerba Research, Synevo Central Labs, Versiti, Cenetron, Ampersand Capital Partners, Pacific Biomarkers, Cirion |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to central lab market will help companies and investors design strategic landscapes.
Biomarker services was the largest segment with a revenue share of 38.62% in 2023. Horizon Databook has segmented the Mexico central lab market based on genetic services, biomarker services, microbiology services, anatomic pathology/histology, specimen management & storage, special chemistry services covering the revenue growth of each sub-segment from 2018 to 2030.
The central lab market in Mexico is expected to grow at a significant rate owing to the presence of a diverse demographic profile and a high potential for patient recruitment. Regulatory authorities in the country, such as the Mexican Institute of Social Security (IMSS) and other national health authorities promote research activities and have potential access to about 70% of the patient population.
The country also has the presence of skilled researchers and professionals in various therapeutic areas including transmissible, non-transmissible, chronic, & rare diseases, representing a large potential for the growth of clinical research prospects.
Furthermore, Mexico has a dynamic pharmaceutical industry, which witnesses the launch of new treatment options within 1 to 3 years of their launch in developed markets of the U.S. or Europe. Hence, the country is anticipated to provide lucrative opportunities for the growth of the central lab market over the forecast period.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico central lab market , including forecasts for subscribers. This country databook contains high-level insights into Mexico central lab market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account